IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, provided a business update including ...

Gothenburg, January 9, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology ...

Exelixis teamed with Natera on the phase III STELLAR-316 study testing zanzalintinib in resected stage II/III colorectal cancer. Stock gains.

Exelixis, Inc. today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 and delivered an update on its business. Exelixis ...

Misconceptions about HCC often lead to stigma, but early detection can significantly improve treatment outcomes and survival ...

How do tertiary lymphoid structures influence immunotherapy outcomes in Merkel cell carcinoma? Spatial proteomics reveals key ...

Exelixis, Inc. and Natera , a global leader in cell-free DNA and precision medicine, today announced their collaboration on the planned Exelixis-sponsored STELLAR-316 trial. This randomized phase 3 ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society ...

A new tool provided a validated tumor recurrence and survival risk score for patients with lymph node-negative PanNETs.

The STELLAR-316 trial will use Natera's Signatera assay to identify MRD-positive patients for trial enrollment and to monitor therapy response.

Cancer survivors can be a source of hope for others navigating life with cancer. Survivors include anyone who has been ...